160,742 Shares in Inogen, Inc $INGN Acquired by Monaco Asset Management SAM

Monaco Asset Management SAM purchased a new stake in Inogen, Inc (NASDAQ:INGN) during the second quarter, according to the company in its most recent filing with the SEC. The firm purchased 160,742 shares of the medical technology company’s stock, valued at approximately $1,037,000. Inogen comprises 0.1% of Monaco Asset Management SAM’s investment portfolio, making the stock its 28th biggest position. Monaco Asset Management SAM owned about 0.59% of Inogen at the end of the most recent quarter.

Several other institutional investors also recently made changes to their positions in INGN. Arrowstreet Capital Limited Partnership increased its position in Inogen by 203.9% during the 1st quarter. Arrowstreet Capital Limited Partnership now owns 586,159 shares of the medical technology company’s stock worth $3,622,000 after purchasing an additional 393,310 shares in the last quarter. Armistice Capital LLC lifted its position in Inogen by 46.3% during the fourth quarter. Armistice Capital LLC now owns 1,264,000 shares of the medical technology company’s stock valued at $8,494,000 after buying an additional 400,000 shares in the last quarter. Assenagon Asset Management S.A. lifted its position in Inogen by 15.5% during the first quarter. Assenagon Asset Management S.A. now owns 51,028 shares of the medical technology company’s stock valued at $315,000 after buying an additional 6,843 shares in the last quarter. Prelude Capital Management LLC purchased a new stake in Inogen during the third quarter worth approximately $82,000. Finally, Quarry LP purchased a new stake in Inogen during the fourth quarter worth approximately $27,000. 89.94% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Separately, Weiss Ratings reiterated a “sell (d-)” rating on shares of Inogen in a research note on Wednesday, August 5th. One research analyst has rated the stock with a Strong Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy”.

Insider Activity

In other news, EVP Boyer Jennifer M. Yi sold 10,938 shares of the company’s stock in a transaction dated Wednesday, July 1st. The shares were sold at an average price of $6.60, for a total value of $72,190.80. Following the sale, the executive vice president owned 5,039 shares in the company, valued at approximately $33,257.40. This represents a 68.46% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Company insiders own 2.50% of the company’s stock.

Inogen Stock Performance

INGN stock opened at $5.75 on Monday. The firm has a 50 day simple moving average of $6.43 and a 200-day simple moving average of $6.37. The company has a market capitalization of $152.60 million, a P/E ratio of -6.39 and a beta of 1.55. Inogen, Inc has a twelve month low of $5.34 and a twelve month high of $9.13.

Inogen (NASDAQ:INGN) last posted its quarterly earnings results on Thursday, August 6th. The medical technology company reported ($0.14) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.15) by $0.01. The firm had revenue of $95.08 million for the quarter, compared to analysts’ expectations of $95.23 million. Inogen had a negative net margin of 6.94% and a negative return on equity of 13.17%. On average, research analysts predict that Inogen, Inc will post -0.77 EPS for the current year.

Inogen Profile

Inogen, Inc (NASDAQ: INGN) is a medical device company specializing in the development, manufacture and marketing of innovative oxygen therapy solutions. The company’s core focus is on portable oxygen concentrators (POCs) designed to support patients with chronic respiratory conditions such as chronic obstructive pulmonary disease (COPD). Inogen’s offerings aim to provide users with mobility and independence by reducing reliance on traditional compressed-gas cylinders and enabling oxygen therapy on the go.

Inogen’s flagship product line, including the Inogen One family of portable oxygen concentrators, leverages proprietary flow technology to deliver continuous and pulse-dose oxygen.